| External factors: | Cisplatin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Chronic kidney disease |
| Experiment: | Cell morphological analysis//SA-β-gal activity assay//Flow cytometry//BrdU assay |
| Description: | NRK cells became enlarged and flattened morphologically. Positive staining for SA-β-Gal was observed at 24 h and increased to 15% at 48 h and 22% at 72 h.Another marker of senescence, C12FDG was also positive in cisplatin-treated cells and most obvious in 20 μM group. Cell cycle analysis showed that 20 μM cisplatin resulted in a marked increase in the percentage of cells in S phase. EdU was detected in cisplatin treated renal tubular cells. There were fewer EdU-positive cells in cisplatin-treated renal tubular cells compared with control group. |
| Target gene: | P53//P21//SIRT1 |
| R-EF-Target gene: | Upregulation//Upregulation//Downregulation |
| Official symbol(s): | P53//P21//SIRT1 |
| Target gene experiment: | Western blot |
| Target gene description: | The p53 and p21 proteins, which are senescence modulators, were upregulated at 48 h after cisplatin treatment .Assessment of SIRT1 levels showed that cisplatin treatment downregulated SIRT1 at the protein level in NRK cells. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: